Press releases

Release
06.12.2017

Positive preclinical results for the active ingredient in VAL-63-NAFLD on non-alcoholic fatty liver, a risk factor for NASH

Download
Release
04.12.2017

Metformin + TOTUM-63 combination: first positive preclinical data for possible use in diabetes real life practice

Download
Release
08.11.2017

VALEDIA®: launch of “pivotal” REVERSE-IT clinical trial to obtain a health claim

Download
Release
16.10.2017

LIPIDRIVE®: efficacy confirmed in three models, finalization of recruitment for Phase I/II in humans

Download
Release
29.09.2017

Consolidated results for the first half of 2017

Download
Release
20.09.2017

International pharmaceutical and nutrition expert Dr. Jean Zetlaoui joins VALBIOTIS’ Supervisory Board

Download
Release
07.09.2017

Pascal SIRVENT appointed Director of Discovery and Preclinical Research

Download
Release
05.09.2017

VALBIOTIS opens a new Clinical Investigation Center at the Institut Pasteur in Lille as part of the Phase IIa study on TOTUM-63, the active ingredient of Valedia®

Download
Release
09.06.2017

Results of Phase I/II clinical study on the active ingredient of Valedia®

Download